France· FR:69607230
ENTYVIO 108 mg, solution injectable en seringue préremplie
A medicinal product containing védolizumab, registered in France by TAKEDA PHARMA (DANEMARK), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- VÉDOLIZUMAB
- Manufacturer
- TAKEDA PHARMA (DANEMARK)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302086632 seringue(s) préremplie(s) en verre de 0,68 ml (conditionnement multiple)EUR 563.71
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Védolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsEntyvio 108 mg, oplossing voor injectie in voorgevulde penTakeda Pharma A/S
- IrelandEntyvio 108 mg solution for injection in pre-filled syringeTakeda Pharma A/S
- FinlandEntyvioTakeda Pharma A/S
- CzechiaENTYVIOTakeda Pharma A/S, Vallensbaek Strand
- SpainENTYVIO 108 MG SOLUCION INYECTABLE EN JERINGA PRECARGADATakeda Pharma A/S
- United KingdomEntyvio 108mg/0.68ml solution for injection pre-filled pensTakeda UK Ltd
- United StatesEntyvioTakeda Pharmaceuticals America, Inc.
- CanadaENTYVIOTAKEDA CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Entyvio
- Liechtenstein · Entyvio
- Norway · Entyvio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/853a4fd9-ea5d-4a4c-9b4f-522a26910684 GET /v1/drugs/853a4fd9-ea5d-4a4c-9b4f-522a26910684?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "69607230",
"date_amm": "2020-04-28",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/14/923",
"substance": "VÉDOLIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about védolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.